The value of appropriate assessment prior to specialist referral in men with prostatic symptoms

Irish Journal of Medical Science

Volumn 178, Issue 3, 2009, Pages 281-285

  Quinlan, M R ^a,b   O'Daly, B J ^a   O'Brien, M F ^a   Gardner, S ^a   Lennon, G ^a   Mulvin, D W ^a   Quinlan, D M ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

Bother; BPH; DRE; IPSS; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BOTHER SCORE; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; GENERAL PRACTITIONER; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PROSTATE HYPERTROPHY; SCORING SYSTEM; HEALTH STATUS INDICATOR; IRELAND; MEDICINE; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; QUALITATIVE RESEARCH; QUESTIONNAIRE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; URINATION DISORDERS;

AGED; HEALTH STATUS INDICATORS; HUMANS; IRELAND; MALE; MEDICINE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITATIVE RESEARCH; QUESTIONNAIRES; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; URINATION DISORDERS;

EID: 77249174898     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-009-0337-1     Document Type: Article

References (24)

1. Wei JT, Calhoun E, Jacobsen SJ (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173(4): 1256-1261. doi:10.1097/01.ju.0000155709.37840.fe (Pubitemid 40380548)
2. Walsh PC (2002) Surgery and the reduction of mortality from prostate cancer. N Engl J Med 347(11):839-840. doi:10.1056/ NEJMe020089
3. Hamilton W, Sharp D (2004) Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract 54(505):617-621 (Pubitemid 39117573)
4. Thompson IM, Ankerst DP, Chi C et al (2006) Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 98(8):529-534 (Pubitemid 43898816)
5. Babaian RJ, Miyashita H, EVans RB, Von Eschenbach AC, Ramirez EI (1991) Early detection program for prostate cancer: results and identification of high-risk patient population. Urology 37(3):193-197. doi:10.1016/0090-4295(91) 80283-D
6. Irani J, Brown CT, Van Der Meulen J, Emberton M (2003) A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same? BJU Int 92(9):937-942. doi:10.1111/j.1464-410X.2003. 04529.x (Pubitemid 37548270)
7. Barry MJ, Fowler FJ Jr, O'Leary MP et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia, The Measurement Committee of the American Urological Association. J Urol 148(5):1549-1557 (discussion 1564)
8. O'Leary MP (2005) Validity of the ''bother score'' in the evaluation and treatment of symptomatic benign prostatic hyperplasia. Rev Urol 7(1):1-10
9. Jepsen JV, Bruskewitz RC (1998) Comprehensive patient evaluation for benign prostatic hyperplasia. Urology 51(4A Suppl):13-18
10. Carballido Rodriguez J, Badia Llach X, Gimeno Collado A, RegaDera Anechina L, Dal-Re Saavedra R, Guilera Sarda M (2006) Validity of tests for initial diagnosis and its concordance with final diagnosis in patients with suspected benign prostatic hyperplasia. Actas Urol Esp 30(7):667-674
11. Fawzy A, Fontenot C, Guthrie R, Baudier MM (1997) Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer. Fam Med 29(5):321-325
12. Quinlan MR, Teahan S, Mulvin D, Quinlan DM (2007) Is digital rectal examination still necessary in the early detection of prostate cancer? Ir J Med Sci 176(3). doi:10.1007/s11845-007-0018-x (Pubitemid 47377511)
13. PeDersen KV, Carlsson P, Varenhorst E, Lofman O, Berglund K (1990) Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 300(6731): 1041-1044
14. Kirby RS, Kirby MG, Feneley MR, McNicholas T, McLean A, Webb JA (1994) Screening for carcinoma of the prostate: a GP based study. Br J Urol 74(1):64-71. doi:10.1111/j.1464-410X. 1994.tb16549.x
15. Casey RG, Quinlan MR, Flynn R, Grainger R, McDermott TE, Thornhill JA (2007) Urology out-patient non-attenDers: are we wasting our time? Ir J Med Sci 176(4):305-308. doi:10.1007/ s11845-007-0028-38
16. Bosch JL, Bohnen AM, Groeneveld FP (2004) Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol 46(6):753-759. doi: 10.1016/j.eururo.2004.07.019 (Pubitemid 39488407)
17. Roehrborn CG, Girman CJ, Rhodes T et al (1997) Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 49(4):548-557. doi: 10.1016/S0090-4295(97)00031- 9 (Pubitemid 27161413)
18. Kaplan SA, Olsson CA, Te AE (1996) The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work? J Urol 155(6):1971-1974. doi:10.1016/S0022- 5347(01)66064-6 (Pubitemid 26144096)
19. Flam T, Montauban V (2003) Screening of clinical benign prostatic hypertrophy in general practice: survey of 18, 540 men. Prog Urol 13(3):416-424
20. McGuire BB, O'Brien MF, McLoughlin S, O'Malley KJ, Fitzpatrick JM (2007) Should patients with symptomatic BPH have a trial of medical therapy by their general practitioner prior to referral for urological assessment? Ir Med J 100(4):428-429
21. Samaritan G, Pearlman RA (2007) UnDerdiagnosed and unDertreated colorectal cancer tops liability list. J Med Assoc Ga 96(1):48
22. Verhamme KM, Dieleman JP, Bleumink GS et al (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur Urol 42(4):323-328. doi:10.1016/S0302-2838(02) 00354-8
23. Bruskewitz R (1999) Management of symptomatic BPH in the US: who is treated and how? Eur Urol 36(Suppl 3):7-13. doi: 10.1159/000052343
24. McNicholas TA (1999) Management of symptomatic BPH in the UK: who is treated and how? Eur Urol 36(Suppl 3):33-39. doi: 10.1159/000052347 (Pubitemid 29507150)